$0.33
(Market cap
$324 Mln
Revenue (TTM)
$11 Mln
P/E Ratio
--
P/B Ratio
27.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
1.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.4
-
Face value
--
-
Shares outstanding
83,408,050
5 Years Aggregate
CFO
$-207.69 Mln
EBITDA
$-281.65 Mln
Net Profit
$-288.71 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Pyxis Oncology Inc (PYXS)
| 238.3 | 28.0 | 128.8 | 164.6 | 18.8 | -- | -- |
|
BSE Sensex*
| -10.1 | -3.6 | 2.5 | -5.7 | 4.9 | 5.5 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Pyxis Oncology Inc (PYXS)
| -26.3 | -13.2 | 34.3 | -87.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Pyxis Oncology Inc (PYXS)
|
3.9 | 324.5 | 11.0 | -88.7 | -793.8 | -273.6 | -- | 27.4 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Pyxis Oncology Inc (PYXS)
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1... (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts. Read more
-
Co-Founder & Independent Chairman
Mr. John L. Flavin M.B.A., MBA, Ph.D.
-
Co-Founder & Independent Chairman
Mr. John L. Flavin M.B.A., MBA, Ph.D.
-
Headquarters
Boston, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Pyxis Oncology Inc (PYXS)
What is the current share price of Pyxis Oncology Inc (PYXS) Today?
The share price of Pyxis Oncology Inc (PYXS) is $3.89 (NASDAQ) as of 04-Sep-2026 16:10 EDT. Pyxis Oncology Inc (PYXS) has given a return of 18.8% in the last 3 years.
What is the current PB & PE ratio of Pyxis Oncology Inc (PYXS)?
Since, TTM earnings of Pyxis Oncology Inc (PYXS) is negative, P/E ratio is not available.
The P/B ratio of Pyxis Oncology Inc (PYXS) is 27.38 times as on 04-Sep-2026, a 414 premium to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.90 |
1.34 |
2024 |
-1.22 |
0.78 |
2023 |
-1.09 |
0.64 |
2022 |
-0.40 |
0.29 |
2021 |
-4.58 |
1.33 |
What is the 52 Week High and Low of Pyxis Oncology Inc (PYXS)?
The 52-week high and low of Pyxis Oncology Inc (PYXS) are Rs 5.55 and Rs 1.03 as of 07-Sep-2026.
What is the market cap of Pyxis Oncology Inc (PYXS)?
Pyxis Oncology Inc (PYXS) has a market capitalisation of $ 324 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Pyxis Oncology Inc (PYXS)?
Before investing in Pyxis Oncology Inc (PYXS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.